Storyline
New insights into CAR T cell therapy resistance and combination strategies in solid tumors
Recent studies reveal mechanisms of resistance to GD2-CAR T cell therapy in diffuse midline glioma (DMG) linked to anti-CAR immune responses, including human anti-CAR antibodies and clonal B cell expansion.
Published 2026-07-09 18:38 UTCUpdated 2026-07-10 05:58 UTC
Current brief openSource links open
This current storyline is open here with summary, metadata, source links, continuity context, and full evidence. Paid is for compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Recent studies reveal mechanisms of resistance to GD2-CAR T cell therapy in diffuse midline glioma (DMG) linked to anti-CAR immune responses, including human anti-CAR antibodies and clonal B cell expansion.
Score total
0.96
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- Recent preclinical and clinical data reveal key resistance pathways and potential combination strategies.
- FDA approval of radioligand therapy enables translational opportunities with CAR T cells.
- Addressing these challenges is critical to advancing CAR T therapies beyond hematological cancers.
Why it matters
- Understanding immune resistance mechanisms can improve CAR T therapy durability in solid tumors.
- Combination therapies may overcome tumor microenvironment barriers limiting CAR T efficacy.
- These insights guide development of more effective treatments for difficult cancers like DMG and mCRPC.
Continuity snapshot
- Trend status: insufficient_history.
- Continuity stage: seed.
- Current status: open.
- 2 current source-linked posts are attached to this storyline.
All evidence
All evidence
Radioligand therapy in combination with CAR T cells overcomes the heterogeneous immunosuppressive prostate tumor microenvironment
bioRxiv (all subjects) · biorxiv.org · 2026-07-10 05:58 UTC
Anti-CAR Immunity Drives Acquired Therapeutic Resistance to GD2-CAR T Cell Therapy in Diffuse Midline Glioma
medRxiv (all subjects) · medrxiv.org · 2026-07-09 18:38 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- bioRxiv (all subjects) (1)
- medRxiv (all subjects) (1)
Top origin domains (this list)
- biorxiv.org (1)
- medrxiv.org (1)